Insider Buying: Sensei Biotherapeutics (NASDAQ:FTH) CFO Acquires $245,386.83 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson acquired 9,391 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The stock was bought at an average price of $26.13 per share, with a total value of $245,386.83. Following the transaction, the chief financial officer directly owned 26,804 shares in the company, valued at $700,388.52. The trade was a 53.93% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Sensei Biotherapeutics Stock Down 7.3%

NASDAQ:FTH traded down $1.80 during trading hours on Friday, hitting $22.87. 145,732 shares of the stock were exchanged, compared to its average volume of 82,691. Sensei Biotherapeutics, Inc. has a twelve month low of $6.32 and a twelve month high of $36.76.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on FTH shares. Robert W. Baird initiated coverage on Sensei Biotherapeutics in a research note on Friday. They set an “outperform” rating and a $57.00 price target on the stock. Weiss Ratings initiated coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating for the company. BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Finally, HC Wainwright assumed coverage on shares of Sensei Biotherapeutics in a research note on Monday. They issued a “buy” rating and a $60.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $58.50.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.